APPLIED DNA SCIENCES, INC. Applied DNA Sciences, Inc. Stock
Equities
APDN
US03815U4094
Medical Equipment, Supplies & Distribution
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.49 USD | -7.77% |
|
-9.94% | -96.06% |
Financials (USD)
| Sales 2024 * | 4.5M | Sales 2025 * | 6.76M | Capitalization | 5.43M |
|---|---|---|---|---|---|
| Net income 2024 * | -12M | Net income 2025 * | -13M | EV / Sales 2024 * | 1.21 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 0.8 x |
| P/E ratio 2024 * |
-0.08
x | P/E ratio 2025 * |
-0.31
x | Employees | 54 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.83% |
More Fundamentals
* Assessed data
More news
Latest transcript on Applied DNA Sciences, Inc.
More recommendations
More press releases
More news
| 1 day | +6.45% | ||
| 1 week | -2.53% | ||
| Current month | -10.83% | ||
| 1 month | -82.75% | ||
| 3 months | -94.51% | ||
| 6 months | -96.50% | ||
| Current year | -95.69% |
1 week
0.48
0.60
1 month
0.483.27
Current year
0.4814.40
1 year
0.4837.20
3 years
0.48162.00
5 years
0.48535.20
10 years
0.487 760.00
| Managers | Title | Age | Since |
|---|---|---|---|
James Hayward
CEO | Chief Executive Officer | 71 | 05-09-27 |
Beth Jantzen
DFI | Director of Finance/CFO | 47 | 13-04-30 |
Lawrence Jung
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yacov Shamash
BRD | Director/Board Member | 74 | 06-03-16 |
Bob Catell
BRD | Director/Board Member | 87 | 16-10-06 |
James Hayward
CEO | Chief Executive Officer | 71 | 05-09-27 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-14 | 0.4863 | -8.47% | 1 492 881 |
| 24-06-13 | 0.5313 | +6.45% | 5,319,895 |
| 24-06-12 | 0.4991 | -4.73% | 1,074,614 |
| 24-06-11 | 0.5239 | -0.68% | 716,912 |
| 24-06-10 | 0.5275 | -2.31% | 871,719 |
Delayed Quote Nasdaq, June 13, 2024 at 03:59 pm EDT
More quotes
Applied DNA Sciences, Inc. is a biotechnology company that develops, and markets deoxyribonucleic acid (DNA) based technology solutions. The Company is utilizing its LinearDNA large-scale polymerase chain reaction (PCR) based manufacturing platform. The Companyâs proprietary platform produces large quantities of DNA for use in the nucleic acid-based in vitro diagnostics and preclinical nucleic-acid based drug development and manufacturing markets and for supply chain security, anti-counterfeiting and anti-theft technology purposes. It also develops PCR-based molecular in vitro diagnostics for covid-19. In addition, under its wholly owned subsidiary, Applied DNA Clinical Labs, LLC, the Company is offering a high-throughput turnkey solution for population-scale Covid-19 testing marketed as safeCircle. safeCircle utilizes the Companyâs Covid-19 Diagnostic Tests and is designed to look for infection within defined populations or communities utilizing high throughput testing methodologies.
Calendar
2024-08-07
- Q3 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.5313
USD
Average target price
1.5
USD
Spread / Average Target
+182.33%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -95.69% | 5.43M | |
| -3.07% | 8.21B | |
| +7.95% | 5.77B | |
| +29.16% | 5.55B | |
| -16.16% | 3.83B | |
| +10.30% | 2.65B | |
| -64.76% | 2.36B | |
| -9.60% | 2.27B | |
| +21.68% | 2.11B | |
| -9.05% | 1.77B |
- Stock Market
- Equities
- APDN Stock
